[go: up one dir, main page]

MX2016002589A - Composicion farmaceutica que contiene compuesto de pirimidina como ingrediente activo. - Google Patents

Composicion farmaceutica que contiene compuesto de pirimidina como ingrediente activo.

Info

Publication number
MX2016002589A
MX2016002589A MX2016002589A MX2016002589A MX2016002589A MX 2016002589 A MX2016002589 A MX 2016002589A MX 2016002589 A MX2016002589 A MX 2016002589A MX 2016002589 A MX2016002589 A MX 2016002589A MX 2016002589 A MX2016002589 A MX 2016002589A
Authority
MX
Mexico
Prior art keywords
fgfr4
pharmaceutical composition
fgf19
active ingredient
related cancer
Prior art date
Application number
MX2016002589A
Other languages
English (en)
Inventor
Takashi Futami
Rumi Takeshita
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of MX2016002589A publication Critical patent/MX2016002589A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dermatology (AREA)

Abstract

Se proporciona una composición farmacéutica para el tratamiento de cáncer relacionado con FGFR4, cáncer relacionado con FGF19, o cáncer de hígado positivo para la amplificación del gen FGF19. Los presentes inventores han perfeccionado la presente invención a través del estudio de compuestos que tienen un efecto inhibitorio sobre FGFR4 verificando que los compuestos específicos de pirimidina tengan un efecto inhibitorio sobre FGFR4 y una composición farmacéutica que tiene estos compuestos como ingredientes activos que tienen un efecto terapéutico contra el cáncer relacionado con FGFR4 o en otra modalidad, cáncer relacionado con FGFI9 y aun en otra modalidad, cáncer de hígado positivo para la amplificación del gen FGF19.
MX2016002589A 2013-08-28 2014-08-27 Composicion farmaceutica que contiene compuesto de pirimidina como ingrediente activo. MX2016002589A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013176355 2013-08-28
PCT/JP2014/072349 WO2015030021A1 (ja) 2013-08-28 2014-08-27 ピリミジン化合物を有効成分とする医薬組成物

Publications (1)

Publication Number Publication Date
MX2016002589A true MX2016002589A (es) 2016-06-14

Family

ID=52586573

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016002589A MX2016002589A (es) 2013-08-28 2014-08-27 Composicion farmaceutica que contiene compuesto de pirimidina como ingrediente activo.

Country Status (16)

Country Link
US (1) US20160199371A1 (es)
EP (1) EP3040072A4 (es)
JP (1) JPWO2015030021A1 (es)
KR (1) KR20160040719A (es)
CN (1) CN105492009A (es)
AR (1) AR097455A1 (es)
AU (1) AU2014312919A1 (es)
CA (1) CA2922352A1 (es)
HK (1) HK1219432A1 (es)
IL (1) IL244206A0 (es)
MX (1) MX2016002589A (es)
PH (1) PH12016500372A1 (es)
RU (1) RU2016106774A (es)
SG (1) SG11201601461RA (es)
TW (1) TW201605452A (es)
WO (1) WO2015030021A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
NZ702747A (en) 2012-06-13 2017-03-31 Incyte Holdings Corp Substituted tricyclic compounds as fgfr inhibitors
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
LT2986610T (lt) 2013-04-19 2018-04-10 Incyte Holdings Corporation Bicikliniai heterociklai, kaip fgfr inhibitoriai
PT3057943T (pt) 2013-10-18 2018-07-24 Eisai R&D Man Co Ltd Inibidores de fgfr4 pirimidina
AU2014338549B2 (en) 2013-10-25 2017-05-25 Novartis Ag Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors
WO2016054483A1 (en) 2014-10-03 2016-04-07 Novartis Ag Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
SG10201913036RA (en) 2015-02-20 2020-02-27 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9802917B2 (en) 2015-03-25 2017-10-31 Novartis Ag Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
JP6431622B2 (ja) 2015-04-14 2018-11-28 エーザイ・アール・アンド・ディー・マネジメント株式会社 結晶性ｆｇｆｒ４阻害剤化合物およびその使用
WO2017196854A1 (en) 2016-05-10 2017-11-16 Eisai R&D Management Co., Ltd. Drug combinations for reducing cell viability and/or cell proliferation
CN107541495B (zh) * 2016-06-28 2022-04-26 上海市东方医院 一种fgf19过表达的人肝癌细胞系及其应用
WO2018055503A1 (en) 2016-09-20 2018-03-29 Novartis Ag Combination comprising a pd-1 antagonist and an fgfr4 inhibitor
US11229643B2 (en) 2016-11-02 2022-01-25 Novartis Ag Combinations of FGFR4 inhibitors and bile acid sequestrants
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
EP3788046B1 (en) 2018-05-04 2025-12-10 Incyte Corporation Salts of an fgfr inhibitor
EP4309737A3 (en) 2018-05-04 2024-03-27 Incyte Corporation Solid forms of an fgfr inhibitor and processes for preparing the same
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CR20220169A (es) 2019-10-14 2022-10-27 Incyte Corp Heterociclos bicíclicos como inhibidores de fgfr
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
KR20220131900A (ko) 2019-12-04 2022-09-29 인사이트 코포레이션 Fgfr 억제제의 유도체
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US20230172867A1 (en) * 2020-05-15 2023-06-08 Eisai R&D Management Co., Ltd. A method for treating cancer with an oral dosage form of an fgfr4 inhibitor
US12065494B2 (en) 2021-04-12 2024-08-20 Incyte Corporation Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent
AR126101A1 (es) 2021-06-09 2023-09-13 Incyte Corp Heterociclos tricíclicos como inhibidores de fgfr
AR126102A1 (es) 2021-06-09 2023-09-13 Incyte Corp Heterociclos tricíclicos como inhibidores de fgfr
EP4509142A1 (en) 2023-08-16 2025-02-19 Ona Therapeutics S.L. Fgfr4 as target in cancer treatment

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007011500A (es) 2005-03-16 2007-11-21 Targegen Inc Compuestos pirimidina y metodos de uso.
US20070149508A1 (en) 2005-11-02 2007-06-28 Targegen, Inc. Six membered heteroaromatic inhibitors targeting resistant kinase mutations
US8030487B2 (en) 2006-07-07 2011-10-04 Targegen, Inc. 2-amino—5-substituted pyrimidine inhibitors
AU2013227139B2 (en) 2012-02-28 2017-02-16 Astellas Pharma Inc. Nitrogen-containing aromatic heterocyclic compound
JP6107812B2 (ja) * 2012-03-08 2017-04-05 アステラス製薬株式会社 新規ｆｇｆｒ３融合体

Also Published As

Publication number Publication date
CN105492009A (zh) 2016-04-13
AU2014312919A1 (en) 2016-03-10
PH12016500372A1 (en) 2016-05-02
CA2922352A1 (en) 2015-03-05
WO2015030021A1 (ja) 2015-03-05
KR20160040719A (ko) 2016-04-14
SG11201601461RA (en) 2016-03-30
US20160199371A1 (en) 2016-07-14
JPWO2015030021A1 (ja) 2017-03-02
TW201605452A (zh) 2016-02-16
AR097455A1 (es) 2016-03-16
EP3040072A4 (en) 2017-03-29
HK1219432A1 (zh) 2017-04-07
EP3040072A1 (en) 2016-07-06
RU2016106774A (ru) 2017-10-03
IL244206A0 (en) 2016-04-21

Similar Documents

Publication Publication Date Title
PH12016500372A1 (en) Pharmaceutical composition containing pyrimidine compound as active ingredient
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
PH12017501306A1 (en) Inhibitors of histone demethylases
PH12015500983A1 (en) Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
PH12015501648B1 (en) 2-aminopyrimidine derivatives for the treatment of viral infections
MY199705A (en) Heterocyclic compounds as immunomodulators
PH12018501084A1 (en) Heterocyclic compounds as immunomodulators
MD20170070A2 (ro) Derivaţi de chinazolină utilizaţi în tratamentul HIV
MX2015014234A (es) Derivados 2-aminopirido-[4,3-d]pirimidin-5-ona y su uso como inhibidores de wee-1.
SG10201907582WA (en) Bicyclic heterocycles as fgfr4 inhibitors
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
BR112014021531A8 (pt) composto, composição farmacêutica e usos dos mesmos
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
ZA201605979B (en) 4'-difluoromethyl substituted nucleoside derivatives as inhibitors of influenza rna replication
EA201391682A1 (ru) Замещенные производные индазола, активные в качестве ингибиторов киназы
PH12015500724A1 (en) 1, 2, 4-triazine derivatives for the treatment of viral infections
IL228600B (en) (Aralkylamino and heteroarylalkylamino alpha-converted) pyrimidinyl and 1,3,5-triazinyl benzaimidazoles, pharmaceutical preparations containing them and use of these compounds in the treatment of proliferative diseases
WO2011160024A3 (en) Compounds useful as antiviral agents, compositions, and methods of use
MX2010009743A (es) Uso de derivados de pirimidina para el tratamiento de las enfermedades dependientes de los receptores del factor de crecimiento epidermico (egfr) o de enfermedades que hayan adquirido resistencia a los agentes que se dirigen a los miembros de la fami
EP3034082A4 (en) Pharmaceutical composition for treating or preventing neuropsychitric disease, containing flavone-6-c-glucose derivatives as active ingredients
PH12015502589A1 (en) 4`-azido, 3`-deoxy-3`-fluoro substituted nucleoside derivatives
WO2016030899A8 (en) Methods of treating amyotrophic lateral scleroses
MX2018014790A (es) Formulacion combinada de tres compuestos antivirales.
MX2016004094A (es) Composicion farmaceutica que comprende capecitabina y ciclofosfamida.